Press Releases David Cook 21/5/24 David Cook 21/5/24 Edgewood Oncology Announces First Patients Dosed in Phase 2a Study of BTX-A51 in Genetically-Defined Breast Cancer Read More David Cook 8/4/24 David Cook 8/4/24 Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma Read More David Cook 25/3/24 David Cook 25/3/24 Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors Read More
David Cook 21/5/24 David Cook 21/5/24 Edgewood Oncology Announces First Patients Dosed in Phase 2a Study of BTX-A51 in Genetically-Defined Breast Cancer Read More
David Cook 8/4/24 David Cook 8/4/24 Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma Read More
David Cook 25/3/24 David Cook 25/3/24 Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors Read More
